Search bioRxivSearch

Biology subjects

Sharan, R.

Publications and source records attributed to Sharan, R..

2 recordsLinked to original sources

Hidden Markov Models Lead to Higher Resolution Maps of Mutation Signature Activity in Cancer

Knowing the activity of the mutational processes shaping a cancer genome may provide insight into tumorigenesis and personalized therapy. It is thus important to uncover the characteristic signatures of active mutational processes in patients from their patterns of single base substitutions. However, mutational processes do not act uniformly on the genome and are biased by factors such as the genomes chromatin structure or replication origins. These factors may lead to statistical dependencies among neighboring mutations, calling for modeling approaches that can account for such dependencies to better estimate mutational process activities.\n\nHere we develop the first sequence-dependent models for mutation signatures. We apply these models to characterize genomic and other factors that influence the activity of previously validated mutation signatures in breast cancer. We find that our tool, SO_SCPLOWIGC_SCPLOWMO_SCPLOWAC_SCPLOW, can accurately assign genomic mutations to mutation signatures, yielding assignments that are of higher likelihood than those obtained with models that assume independence between signatures and align better with current biological knowledge. Our analysis resolves a controversy related to the dependency of APOBEC signatures on replication time and links Signatures 18 and 30 to oxidative damage.\n\nModeling the sequential dependencies of mutation signatures leads to improved estimates of mutation signature activity both at the tumor-level and within specific genomic regions, yielding higher resolution maps of mutation signature activity in cancer.

bioinformatics

ModulOmics: Integrating Multi-Omics Data to Identify Cancer Driver Modules

The identification of molecular pathways driving cancer progression is a fundamental unsolved problem in tumorigenesis, which can substantially further our understanding of cancer mechanisms and inform the development of targeted therapies. Most current approaches to address this problem use primarily somatic mutations, not fully exploiting additional layers of biological information. Here, we describe ModulOmics, a method to de novo identify cancer driver pathways, or modules, by integrating multiple data types (protein-protein interactions, mutual exclusivity of mutations or copy number alterations, transcriptional co-regulation, and RNA co-expression) into a single probabilistic model. To efficiently search the exponential space of candidate modules, ModulOmics employs a two-step optimization procedure that combines integer linear programming with stochastic search. Across several cancer types, ModulOmics identifies highly functionally connected modules enriched with cancer driver genes, outperforming state-of-the-art methods. For breast cancer subtypes, the inferred modules recapitulate known molecular mechanisms and suggest novel subtype-specific functionalities. These findings are supported by an independent patient cohort, as well as independent proteomic and phosphoproteomic datasets.

cancer biology